GlaxoSmithKline’s weight loss pill Alli is selling like a hot cake. In their next stride, GlaxoSmithKline has appointed WCRS to handle the £30m advertising for the pan-European launch of its weight loss ‘wonder-drug' Alli.

Alli is the first ever weight loss drug that has got approval from FDA as an over-the-counter treatment in the US in February. It works by blocking the enzymes that break down some of the fat in the foods you eat so the drug prevents the body from absorbing at least 25% of that fat as calories.

The drug maker, GlaxoSmithKline says as long as users follow a healthy lifestyle they can lose 50% more weight with Alli than by just dieting alone. That means if you can lose 10 pounds through dieting, Alli can help you lose 15 pounds.

GSK plans to launch the drug, which works by absorbing up to 25% of fat of a person's consumption, in Europe towards the end of next year. The US ad account is handled by Arnold Worldwide.

Alli diet pill gained sales of £76m in the second quarter of the year. By October, after being on sale for four months, GSK had sold more than two million starter packs of Alli, which retails at approximately £30 for a 90-pill package. And the total sale is estimated $150 million since the first FDA-approval.